Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial

Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial

Abstract Background MYC genes regulate ornithine decarboxylase (Odc) to increase intratumoral polyamines. We conducted a Phase I trial [NCT02030964] to determine the maximum tolerated dose (MTD) of DFMO, an Odc inhibitor, with celecoxib, cyclophosphamide and topotecan. Methods Patients 2–30 years of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Michael D. Hogarty, David S. Ziegler, Andrea Franson, Yueh‐Yun Chi, Denice Tsao‐Wei, Kangning Liu, Rohan Vemu, Eugene W. Gerner, Elizabeth Bruckheimer, Anasheh Shamirian, Beth Hasenauer, Frank M. Balis, Susan Groshen, Murray D. Norris, Michelle Haber, Julie R. Park, Katherine K. Matthay, Araz Marachelian
Format: Artigo
Sprache:Englisch
Veröffentlicht: 2024
Online-Zugang:https://doi.org/10.1038/s41416-023-02525-2
https://www.nature.com/articles/s41416-023-02525-2.pdf
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Online

https://doi.org/10.1038/s41416-023-02525-2
https://www.nature.com/articles/s41416-023-02525-2.pdf

Ähnliche Einträge